Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MM-111 + trastuzumab
- Development stage
- Phase 1
- Lead developer
- Merrimack Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MM-111 + trastuzumab is a combination therapy under investigation for the treatment of HER2-positive cancers, particularly breast and gastroesophageal (GE) cancers. MM-111 is a novel bispecific antibody fusion protein that specifically targets the HER2/HER3 heterodimer, blocking heregulin-induced activation of HER3 and downstream signaling pathways associated with tumor growth and resistance to anti-HER2 therapies. Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of Human epidermal growth factor receptor 2 (HER2), inhibiting proliferation and survival of cancer cells overexpressing this receptor. The combination aims to overcome resistance mechanisms mediated by HER3 activation in tumors treated with anti-HER2 agents like trastuzumab. Clinical trials have evaluated this combination in advanced breast cancer and GE junction/gastric adenocarcinoma[5][6][8].
- Brand names
- Herceptin (for trastuzumab)
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on MM-111 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MM-111 + trastuzumab.